Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Garden, Adam S ^a   Kies, Merrill S ^a   Morrison, William H ^a   Weber, Randal S ^a   Frank, Steven J ^a   Glisson, Bonnie S ^a   Gunn, Gary B ^a   Beadle, Beth M ^a   Ang, K Kian ^a   Rosenthal, David I ^a   Sturgis, Erich M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiation; IMRT; Oropharyngeal cancer; Radiation; Squamous cell

Indexed keywords

CARBOPLATIN; CETUXIMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTROSTOMY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; RECURRENCE FREE SURVIVAL; SMOKING; SQUAMOUS CARCINOMA OF THE OROPHARYNX; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HISTORY, 21ST CENTURY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84872943511     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-21     Document Type: Article

References (31)

1. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006, 368:843-854. 10.1016/S0140-6736(06)69121-6, 16950362.
2. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000, 48:7-16. 10.1016/S0360-3016(00)00663-5, 10924966.
3. Overgaard J, Hansen H, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003, 362:933-940. 10.1016/S0140-6736(03)14361-9, 14511925.
4. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14. 10.1016/j.radonc.2009.04.014, 19446902.
5. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357:1705-1715. 10.1056/NEJMoa070956, 17960013.
6. Chao K, Ozyigit G, Blanco A, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 2004, 59:43-50. 10.1016/j.ijrobp.2003.08.004, 15093897.
7. Eisbruch A. Intensity-modulated radiotherapy of head-and-neck cancer: encouraging early results. Int J Radiat Oncol Biol Phys 2002, 53:1-3. 10.1016/S0360-3016(02)02725-6, 12007933.
8. Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 2009, 76:1333-1338. 2846217, 19540060.
9. Guadagnolo BA, Liu CC, Cormier JN, Du XL. Evaluation of trends in the use of intensity-modulated radiotherapy for head and neck cancer from 2000 through 2005: socioeconomic disparity and geographic variation in a large population-based cohort. Cancer 2010, 116:3505-3512. 10.1002/cncr.25205, 20564123.
10. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the united states. J Clin Oncol 2008, 26:612-619. 10.1200/JCO.2007.14.1713, 18235120.
11. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007, 356:1944-1956. 10.1056/NEJMoa065497, 17494927.
12. Sturgis EM, Ang KK. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms?. J Natl Compr Canc Netw 2011, 9:665-673.
13. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35. 10.1056/NEJMoa0912217, 2943767, 20530316.
14. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010, 28:4142-4148. 10.1200/JCO.2010.29.2904, 2953971, 20697079.
15. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009, 27:6213-6221. 10.1200/JCO.2009.23.1670, 19884544.
16. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010, 28:8-14. 10.1200/JCO.2009.23.0425, 2799235, 19917840.
17. Garden AS, Asper JA, Morrison WH, et al. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?. Cancer 2004, 100:1171-1178. 10.1002/cncr.20069, 15022283.
18. Pytynia KB, Grant JR, Etzel CJ, Roberts DB, Wei Q, Sturgis EM. Matched-pair analysis of survival of never smokers and ever smokers with squamous cell carcinoma of the head and neck. J Clin Oncol 2004, 22:3981-3988. 10.1200/JCO.2004.02.133, 15459221.
19. American Joint Committee on Cancer Staging Manual for staging of cancer 2002, Philadelphia: J. B. Lippincott, American Joint Committee on Cancer Staging.
20. Thariat J, Ang KK, Allen PK, et al. Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2011, 82:e367-374.
21. Garden AS, Harris J, Trotti A, et al. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys 2008, 71:1351-1355. 10.1016/j.ijrobp.2008.04.006, 2582390, 18640496.
22. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011, 29(suppl):5500.
23. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578. 10.1056/NEJMoa053422, 16467544.
24. Tsao AS, Garden AS, Kies MS, et al. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2006, 24:4163-4169. 10.1200/JCO.2006.05.7851, 16943532.
25. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012, 30:2102-2111. 10.1200/JCO.2011.38.4099, 22565003.
26. Gwozdz JT, Morrison WH, Garden AS, Weber RS, Ang KK, Peters LJ. Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. Int J Radiat Oncol Biol Phys 1997, 39:125-135.
27. Mak AC, Morrison WH, Garden AS, Ang KK, Goepfert H, Peters LJ. Base-of-tongue carcinoma: treatment results using concomitant boost radiotherapy. Int J Radiat Oncol Biol Phys 1995, 33:289-296. 10.1016/0360-3016(95)00088-G, 7673016.
28. Peters LJ, Weber RS, Morrison WH, Byers RM, Garden AS, Goepfert H. Neck surgery in patients with primary oropharyngeal cancer treated by radiotherapy. Head Neck 1996, 18:552-559. 10.1002/(SICI)1097-0347(199611/12)18:6<552::AID-HED10>3.0.CO;2-A, 8902569.
29. Groome P, Schulze K, Mackillop W, et al. A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. Cancer 2001, 92:1484-1494. 10.1002/1097-0142(20010915)92:6<1484::AID-CNCR1473>3.0.CO;2-W, 11745226.
30. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100:261-269. 10.1093/jnci/djn011, 18270337.
31. Chronowski GM, Garden AS, Morrison WH, et al. Unilateral radiotherapy for the treatment of tonsil cancer. Int J Radiat Oncol Biol Phys 2012, 83:204-209. 10.1016/j.ijrobp.2011.06.1975, 22019242.